Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of MDMA-assisted psychotherapy for severe post-traumatic stress disorder
MOH_2018-11-21_002202Phase 3Completed
- Sponsor
- Lykos Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Lykos Therapeutics. Primary endpoint: Change in CAPS-5 total severity score. Started Oct 2018; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on MOH_2018-11-21_002202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-21_002202.